Ankündigung • May 08
ImmuCell Corporation to Report Q1, 2026 Results on May 14, 2026 ImmuCell Corporation announced that they will report Q1, 2026 results After-Market on May 14, 2026 Board Change • May 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Gilles Guillemette was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 15
ImmuCell Corporation, Annual General Meeting, Jun 11, 2026 ImmuCell Corporation, Annual General Meeting, Jun 11, 2026. Location: telephone conference call, United States Ankündigung • Apr 14
ImmuCell Corporation Announces Board Changes ImmuCell Corporation announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. Dr. Guillemette has more than 30 years of executive experience in animal health therapeutics. He has held executive positions at Elanco, Bayer, Henry Schein, Chewy, and Trupanion, where he had significant P&L responsibilities, led strategy, business development and finance functions, and managed regulated therapeutic operations. Dr. Guillemette is currently an Operating Partner at Archimed and earned his Doctor of Veterinary Medicine in Nantes, France. He will Chair the new Strategy and Technology Committee and serve on the Audit Committee. Dr. DiMarco brings four decades of scientific leadership in human and animal health biologics companies. For 21 years, he was Vice President of R&D and Global Manufacturing at IDEXX where he developed new products and implemented productivity improvements. Previously, Dr. DiMarco spent 10 years in scientific roles at Abbott Laboratories. Dr. DiMarco serves as Chair of Educate Maine and received his Ph.D. in Microbiology from the University of Illinois. He will serve on the Compensation, Nominations, and Strategy & Technology Committees. The Company is moving to a 7-person Board of Directors with six Independent Directors and the CEO. Effective April 15, 2026, the independent members of the Board of Directors of ImmuCell will be Dr. David Tomsche DVM (Chair), Ms. Gloria Basse, Dr. Anthony DiMarco Ph.D., Dr. Gilles Guillemette DVM, Ms. Kathy Turner, and Mr. Paul Wainman. The Company also announced it will create a Strategy and Technology Committee of the Board of Directors. Bryan Gathagan and non-independent members Michael Brigham and Bobbi Brockmann will retire from the Board effective April 15, 2026, and Timothy Fiori will retire from the Board after the 2026 Annual Meeting. Ms. Brockmann and Mr. Fiori will continue their executive roles at the Company. Board Change • Apr 02
Less than half of directors are independent Following Director Kathy Turner's arrival on 01 April 2026, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Bryan Gathagan was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Mar 19
Immucell Corporation Announces Changes to Its Board, Effective April 1, 2026 ImmuCell Corporation announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee. Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcare and animal health markets and previously served on the Board of Directors of Elanco Animal Health. From 2014 to 2023, she held senior leadership roles at IDEXX Laboratories, including most recently serving as Chief Marketing Officer and Senior Vice President of International Operations, where she contributed to sustained double-digit growth across international markets. Prior to that, Ms. Turner spent nearly 30 years at Abbott Laboratories, where she held multiple leadership roles in global commercial operations, including responsibility for European markets. Ms. Turner received a B.S. in Marketing and Advertising from Syracuse University. Reported Earnings • Mar 06
Full year 2025 earnings released: US$0.12 loss per share (vs US$0.26 loss in FY 2024) Full year 2025 results: US$0.12 loss per share (improved from US$0.26 loss in FY 2024). Revenue: US$27.6m (up 4.3% from FY 2024). Net loss: US$1.04m (loss narrowed 52% from FY 2024). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 12
Steven A. Rosgen and Bryan K. Gathagan Have Decided Not to Seek Re-Election as Directors of ImmuCell Corporation Two Company directors (Steven A. Rosgen and Bryan K. Gathagan) have separately given notice that they prefer not to run for re-election at the 2026 Annual Meeting of Shareholders. Both have been supportive of ImmuCell Corporation’s new strategic direction and management team, but each cited time constraints from full-time leadership roles at their respective companies. The Nominating Committee has recently been evaluating possible changes in composition of the Board of Directors and will now factor those future retirements into its ongoing work. Ankündigung • Dec 25
ImmuCell Corporation to Report Fiscal Year 2025 Results on Feb 25, 2026 ImmuCell Corporation announced that they will report fiscal year 2025 results on Feb 25, 2026 Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$5.64, the stock trades at a trailing P/E ratio of 22x. Average trailing P/E is 19x in the Biotechs industry in the US. Total loss to shareholders of 16% over the past three years. Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to US$4.60, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 17x in the Biotechs industry in the US. Total loss to shareholders of 28% over the past three years. Reported Earnings • Nov 16
Third quarter 2025 earnings released: US$0.015 loss per share (vs US$0.086 loss in 3Q 2024) Third quarter 2025 results: US$0.015 loss per share (improved from US$0.086 loss in 3Q 2024). Revenue: US$5.51m (down 8.4% from 3Q 2024). Net loss: US$139.7k (loss narrowed 80% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Ankündigung • Nov 07
ImmuCell Corporation to Report Q3, 2025 Results on Nov 13, 2025 ImmuCell Corporation announced that they will report Q3, 2025 results After-Market on Nov 13, 2025 Buy Or Sell Opportunity • Oct 23
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.3% to US$6.06. The fair value is estimated to be US$8.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Oct 02
Now 20% undervalued Over the last 90 days, the stock has risen 2.4% to US$6.55. The fair value is estimated to be US$8.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: US$0.056 (vs US$0.20 loss in 2Q 2024) Second quarter 2025 results: EPS: US$0.056 (up from US$0.20 loss in 2Q 2024). Revenue: US$6.44m (up 18% from 2Q 2024). Net income: US$501.9k (up US$2.03m from 2Q 2024). Profit margin: 7.8% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Ankündigung • Aug 07
ImmuCell Corporation to Report Q2, 2025 Results on Aug 14, 2025 ImmuCell Corporation announced that they will report Q2, 2025 results After-Market on Aug 14, 2025 New Risk • Jul 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (US$57.8m market cap). New Risk • May 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (US$50.1m market cap). Reported Earnings • May 15
First quarter 2025 earnings released: EPS: US$0.16 (vs US$0.056 loss in 1Q 2024) First quarter 2025 results: EPS: US$0.16 (up from US$0.056 loss in 1Q 2024). Revenue: US$8.07m (up 11% from 1Q 2024). Net income: US$1.45m (up US$1.88m from 1Q 2024). Profit margin: 18% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Ankündigung • Apr 28
ImmuCell Corporation, Annual General Meeting, Jun 12, 2025 ImmuCell Corporation, Annual General Meeting, Jun 12, 2025. Ankündigung • Apr 07
ImmuCell Corporation Appoints Timothy C. Fiori as Chief Financial Officer ImmuCell Corporation announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activities. Ankündigung • Apr 03
ImmuCell Corporation Announces Initiation of Investigational Product Use of Re-Tain ImmuCell Corporation announced that it is initiating Investigational Product use of Re-Tain®. The Company intends to use this opportunity to test market acceptance of the product through a controlled launch. The Company made its Non-Administrative New Animal Drug Application (NADA) submission, that included its fourth submission of the CMC Technical Section, together with the minor technical sections covering All Other Information and Product Labeling during early January of 2025. Clearing inspectional observations at the facilities of the Company’s contract manufacturer is still the critical path constraint to NADA approval. Reported Earnings • Apr 02
Full year 2024 earnings released: US$0.26 loss per share (vs US$0.74 loss in FY 2023) Full year 2024 results: US$0.26 loss per share (improved from US$0.74 loss in FY 2023). Revenue: US$26.5m (up 52% from FY 2023). Net loss: US$2.16m (loss narrowed 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. New Risk • Feb 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (US$45.4m market cap). Reported Earnings • Feb 26
Full year 2024 earnings released: US$0.26 loss per share (vs US$0.74 loss in FY 2023) Full year 2024 results: US$0.26 loss per share (improved from US$0.74 loss in FY 2023). Revenue: US$26.5m (up 52% from FY 2023). Net loss: US$2.16m (loss narrowed 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Ankündigung • Feb 20
ImmuCell Corporation to Report Q4, 2024 Results on Feb 25, 2025 ImmuCell Corporation announced that they will report Q4, 2024 results After-Market on Feb 25, 2025 New Risk • Nov 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (US$33.3m market cap). Reported Earnings • Nov 15
Third quarter 2024 earnings released: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023) Third quarter 2024 results: US$0.086 loss per share (improved from US$0.12 loss in 3Q 2023). Revenue: US$6.01m (up 11% from 3Q 2023). Net loss: US$701.7k (loss narrowed 25% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. Ankündigung • Nov 07
ImmuCell Corporation to Report Q3, 2024 Results on Nov 13, 2024 ImmuCell Corporation announced that they will report Q3, 2024 results After-Market on Nov 13, 2024 Reported Earnings • Aug 15
Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023) Second quarter 2024 results: US$0.20 loss per share (further deteriorated from US$0.18 loss in 2Q 2023). Revenue: US$5.47m (up 55% from 2Q 2023). Net loss: US$1.53m (loss widened 11% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. New Risk • Aug 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$913k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$913k free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$28.1m market cap). Ankündigung • Aug 11
ImmuCell Corporation to Report Q2, 2024 Results on Aug 13, 2024 ImmuCell Corporation announced that they will report Q2, 2024 results After-Market on Aug 13, 2024 Ankündigung • Jun 06
ImmuCell Corporation Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® ImmuCell Corporation provided a regulatory update on the status of its product development initiative for Re-Tain®. As previously disclosed, the Company recently received a Technical Section Incomplete Letter (Incomplete Letter) from the United States Food and Drug Administration (FDA) in response to its third submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section (which is its fifth and final major Technical Section required for its New Animal Drug Application (NADA)). Since then, the Company has prepared the fourth submission of its CMC Technical Section, responding to the comments provided in the Incomplete Letter that are not complex. This submission has not been made yet because all inspectional observations must be cleared at both the Company’s Drug Substance facility and at the Drug Product facility of its contract manufacturer before the FDA will issue a Technical Section Complete Letter. The FDA recently confirmed ImmuCell’s inspectional status as acceptable. ImmuCell’s contract manufacturer expects to submit responses to its inspectional observations around the end of June of 2024. Clearing the outstanding inspectional observations with the FDA defines the critical path timeline. Once the facility inspection at the Drug Product facility of the Company’s contract manufacturer is cleared by the FDA, the Company anticipates submitting a Non-Administrative NADA that would include the Company’s fourth submission of the CMC Technical Section, together with the minor technical sections covering All Other Information and Product Labeling. By statute, this submission would be subject to a review period of up to 180 days. However, the Company believes that a shorter review period may be provided because the responses to the CMC Incomplete Letter are not complex. The goal of submitting this combined filing would be to eliminate the need for an additional 60-day review period of an Administrative NADA submission at the end of the application process, after all five major Technical Section Complete Letters are received. Upon FDA approval, the Company intends to implement its previously disclosed limited distribution, controlled launch strategy with product expiration dating estimated at between the second quarter of 2025 and the first quarter of 2026, subject to final product shelf-life disposition by the FDA. Reported Earnings • May 16
First quarter 2024 earnings released: US$0.056 loss per share (vs US$0.30 loss in 1Q 2023) First quarter 2024 results: US$0.056 loss per share (improved from US$0.30 loss in 1Q 2023). Revenue: US$7.26m (up 111% from 1Q 2023). Net loss: US$437.9k (loss narrowed 81% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Ankündigung • May 10
ImmuCell Corporation to Report Q1, 2024 Results on May 14, 2024 ImmuCell Corporation announced that they will report Q1, 2024 results After-Market on May 14, 2024 Ankündigung • Apr 28
ImmuCell Corporation, Annual General Meeting, Jun 13, 2024 ImmuCell Corporation, Annual General Meeting, Jun 13, 2024, at 09:30 US Eastern Standard Time. Agenda: To elect a Board of Directors to serve until the next Annual Meeting of Stockholders and until their successors are qualified and elected; To consider a non-binding advisory resolution on the Company’s executive compensation program; To ratify the selection by the Audit Committee of the Board of Directors of Wipfli LLP as the Independent Registered Public Accounting Firm for the Company for the year ending December 31, 2024. Ankündigung • Apr 10
ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million. ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Feb 29
Full year 2023 earnings released: US$0.74 loss per share (vs US$0.32 loss in FY 2022) Full year 2023 results: US$0.74 loss per share (further deteriorated from US$0.32 loss in FY 2022). Revenue: US$17.5m (down 5.9% from FY 2022). Net loss: US$5.78m (loss widened 132% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance. Ankündigung • Feb 17
ImmuCell Corporation to Report Q4, 2023 Results on Feb 27, 2024 ImmuCell Corporation announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 27, 2024 Reported Earnings • Nov 16
Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.085 loss in 3Q 2022) Third quarter 2023 results: US$0.12 loss per share (further deteriorated from US$0.085 loss in 3Q 2022). Revenue: US$5.40m (up 13% from 3Q 2022). Net loss: US$940.0k (loss widened 44% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 13
Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.088 loss in 2Q 2022) Second quarter 2023 results: US$0.18 loss per share (further deteriorated from US$0.088 loss in 2Q 2022). Revenue: US$3.53m (down 8.5% from 2Q 2022). Net loss: US$1.38m (loss widened 102% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 08
ImmuCell Corporation to Report Q2, 2023 Results on Aug 10, 2023 ImmuCell Corporation announced that they will report Q2, 2023 results After-Market on Aug 10, 2023 Board Change • Jun 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Gloria Basse was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Ankündigung • Jun 22
ImmuCell Corporation Appoints Bryan K. Gathagan to Board of Directors ImmuCell Corporation announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix, he was a senior executive and Vice President of IT and Finance for Intervet Inc. and oversaw various finance, IT, and general business functions between 1998 to 2008, including 3 years in a global role based in The Netherlands. Before entering the animal health industry, he served as a Vice President at MBNA and Norwest Bank responsible for various IT functions and started his career in IT roles at the University of Maryland, Baltimore County (UMBC). He holds a BS in Information Systems Management from UMBC and an MS in Business from Johns Hopkins University. Reported Earnings • May 12
First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.095 profit in 1Q 2022) First quarter 2023 results: US$0.30 loss per share (down from US$0.095 profit in 1Q 2022). Revenue: US$3.45m (down 43% from 1Q 2022). Net loss: US$2.32m (down 415% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Ankündigung • May 05
ImmuCell Corporation to Report Q1, 2023 Results on May 11, 2023 ImmuCell Corporation announced that they will report Q1, 2023 results After-Market on May 11, 2023 Reported Earnings • Apr 01
Full year 2022 earnings released: US$322 loss per share (vs US$10.31 loss in FY 2021) Full year 2022 results: US$322 loss per share (further deteriorated from US$10.31 loss in FY 2021). Revenue: US$18.6b (down 3.5% from FY 2021). Net loss: US$2.49b (loss widened US$2.42b from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 175 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 22
Full year 2022 earnings released: US$0.32 loss per share (vs US$0.01 loss in FY 2021) Full year 2022 results: US$0.32 loss per share (further deteriorated from US$0.01 loss in FY 2021). Revenue: US$18.6m (down 3.5% from FY 2021). Net loss: US$2.49m (loss widened US$2.42m from FY 2021). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 16
ImmuCell Corporation to Report Fiscal Year 2022 Results on Feb 21, 2023 ImmuCell Corporation announced that they will report fiscal year 2022 results After-Market on Feb 21, 2023 Board Change • Feb 10
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Director Gloria Basse was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Feb 03
David S. Cunningham Intends to Retire from the Board of Directors of David S. Cunningham On January 24, 2023, David S. Cunningham notified ImmuCell Corporation of his intention to retire from the Board of Directors effective immediately following the company's 2023 Annual Meeting to be held on June 15, 2023. Mr. Cunningham's decision to retire from the Board does not arise from any disagreement with the company on any matter relating to the Company's operations, policies, practices or otherwise. Reported Earnings • Aug 12
Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.018 profit in 2Q 2021) Second quarter 2022 results: US$0.088 loss per share (down from US$0.018 profit in 2Q 2021). Revenue: US$3.86m (down 15% from 2Q 2021). Net loss: US$684.1k (down US$825.3k from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 13
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: US$0.095 (up from US$0.061 loss in 1Q 2021). Revenue: US$6.00m (up 46% from 1Q 2021). Net income: US$735.7k (up US$1.18m from 1Q 2021). Profit margin: 12% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Director Gloria Basse was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 09
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Director Gloria Basse was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 04
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: US$0.01 loss per share (up from US$0.14 loss in FY 2020). Revenue: US$19.2m (up 25% from FY 2020). Net loss: US$78.0k (loss narrowed 92% from FY 2020). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 42%. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 26
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: US$0.01 loss per share (up from US$0.14 loss in FY 2020). Revenue: US$19.2m (up 25% from FY 2020). Net loss: US$78.0k (loss narrowed 92% from FY 2020). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 42%. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS US$0.019 (vs US$0.045 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$5.15m (up 38% from 3Q 2020). Net income: US$147.8k (up US$470.7k from 3Q 2020). Profit margin: 2.9% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 14
Second quarter 2021 earnings released: EPS US$0.018 (vs US$0.11 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$4.54m (up 53% from 2Q 2020). Net income: US$141.1k (up US$906.9k from 2Q 2020). Profit margin: 3.1% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Executive Departure • Jun 22
Independent Director Jonathan Rothschild has left the company On the 16th of June, Jonathan Rothschild's tenure as Independent Director ended after 20.2 years in the role. We don't have any record of a personal shareholding under Jonathan's name. Jonathan is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.33 years. Reported Earnings • May 16
First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.017 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$4.11m (down 16% from 1Q 2020). Net loss: US$441.3k (loss widened 261% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Apr 18
Insider recently bought US$1.5m worth of stock On the 14th of April, Sandra Pessin bought around 182k shares on-market at roughly US$8.25 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Apr 05
Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$15.3m (up 12% from FY 2019). Net loss: US$1.02m (loss narrowed 21% from FY 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 24
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 42%. Over the next year, revenue is forecast to grow 8.6%, compared to a 888% growth forecast for the Biotechs industry in the US. Reported Earnings • Feb 24
Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$15.3m (up 12% from FY 2019). Net loss: US$1.02m (loss narrowed 21% from FY 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 06
New 90-day high: US$11.02 The company is up 100% from its price of US$5.50 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period. Is New 90 Day High Low • Jan 19
New 90-day high: US$6.65 The company is up 15% from its price of US$5.77 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 22
New 90-day high: US$6.42 The company is up 22% from its price of US$5.28 on 22 September 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period. Is New 90 Day High Low • Dec 01
New 90-day high: US$6.23 The company is up 15% from its price of US$5.42 on 01 September 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: US$0.045 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$3.72m (up 25% from 3Q 2019). Net loss: US$322.9k (loss narrowed 36% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.